Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MUC1.TR2.4-1BB CAR-T cells
- Development stage
- Preclinical
- Lead developer
- Baylor College of Medicine
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
MUC1.TR2.4-1BB CAR-T cells are genetically engineered autologous T cells designed to target mucin 1 (MUC1)-expressing solid tumors, specifically breast cancer, while overcoming the immunosuppressive tumor microenvironment (TME). Developed by researchers at the Baylor College of Medicine and the National Cancer Institute, these CAR-T cells co-express a novel chimeric co-stimulatory receptor, TR2.4-1BB. This receptor consists of a single-chain variable fragment (scFv) derived from a TRAIL receptor 2 (TR2/TNFRSF10B) agonistic monoclonal antibody (DS-8273a) fused to a 4-1BB (TNFRSF9) intracellular co-stimulatory endodomain. Upon engagement with TR2 expressed on myeloid-derived suppressor cells (MDSCs) within the TME, the TR2.4-1BB receptor induces MDSC apoptosis and simultaneously delivers a co-stimulatory signal to the CAR-T cells, enhancing their proliferation, persistence, and antitumor efficacy.
- Other names
- CAR.MUC1.TR2.4-1BB T cellsCAR.MUC1.TR2.41BB T cellsMUC1.TR2.4-1BB CARTsMUC-1.TR2.4-1BB CARTsMUC 1.TR2.4-1BB CARTs
02
Targets
TNFRSF10B (DR5)MUC1 (Mucin-1 Antigen)TNFRSF9 (CD137 extracellular domain)
Beyond the preview
Go deeper on MUC1.TR2.4-1BB CAR-T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MUC1.TR2.4-1BB CAR-T cells.